Subscribe To
INZY / Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the Upgrade
INZY News
By Zacks Investment Research
October 10, 2023
Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the Upgrade
Inozyme Pharma, Inc. (INZY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might more_horizontal
By PennyStocks
August 4, 2023
3 Penny Stocks To Buy According To Insiders In August 2023
Penny stocks are an interesting asset class when it comes to making money in the stock market. Their inherent risk/reward makeup lends to heavy specul more_horizontal
By GlobeNewsWire
June 2, 2023
Inozyme Pharma to Present at the Jefferies Healthcare Conference
BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing nove more_horizontal
By Seeking Alpha
February 21, 2023
Inozyme Pharma: Rare Disease Player Merits Revaluation Higher After POC Data
Shares are down 58% over the past year. Enzyme replacement therapy is an attractive area of drug development with less risk than more exotic modalitie more_horizontal
By Benzinga
July 20, 2022
Inozyme Pharma Post Encouraging Early Data From Genetic Disorder Trial
Inozyme Pharma Inc (NASDAQ: INZY) has announced preliminary biomarker, safety, and pharmacokinetic (PK) data from the first three subjects in the P more_horizontal
By Benzinga
April 12, 2022
Inozyme Pharma Starts Dosing In INZ-701 Trial For Calcification Disorders
Inozyme Pharma Inc (NASDAQ: INZY) has dosed the first patient in its Phase 1/2 trial of INZ-701 in adult patients with ABCC6 Deficiency. Also, the more_horizontal
By Benzinga
April 4, 2022
Why Inozyme Pharma Shares Are Jumping Today
Inozyme Pharma Inc (NASDAQ: INZY) announced preliminary biomarker, safety, and pharmacokinetic (PK) data from the first three patients treated in t more_horizontal